Tight compensation of glycaemia and vascular complications in patients with type 2 diabetes mellitus - ADVANCE study
Abstract
The ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) study was designed to evaluate the effect of reducing glycated hemoglobin to 6.5% or less on the incidence of severe vascular complications in a large group of patients with diabetes mellitus (DM). ) Type 2. The arm of the study, which ended in June 2007, assessed the effect of lowering blood pressure with the perindopril / indapamide combination, and the results showed a reduction in the risk of serious vascular complications and death, regardless of baseline blood pressure.
In the second arm of the ADVANCE study, the aim was to compare the effect of standard treatment and the intensive reduction of hyperglycaemia with gliclazide MR-based treatment (controlled-release tablets) in reducing the risk of vascular complications.